Turner, Richard Myles 
ORCID: 0000-0002-7315-679X and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2020)
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.
JOURNAL OF CLINICAL MEDICINE, 9 (1).
E22-.
|
Text
jcm-09-00022-v2.pdf - Published version Download (1MB) | Preview |
Abstract
Statins are a cornerstone in the pharmacological prevention of cardiovascular disease. Although generally well tolerated, a small subset of patients experience statin-related myotoxicity (SRM). SRM is heterogeneous in presentation; phenotypes include the relatively more common myalgias, infrequent myopathies, and rare rhabdomyolysis. Very rarely, statins induce an anti-HMGCR positive immune-mediated necrotizing myopathy. Diagnosing SRM in clinical practice can be challenging, particularly for mild SRM that is frequently due to alternative aetiologies and the nocebo effect. Nevertheless, SRM can directly harm patients and lead to statin discontinuation/non-adherence, which increases the risk of cardiovascular events. Several factors increase systemic statin exposure and predispose to SRM, including advanced age, concomitant medications, and the nonsynonymous variant, rs4149056, in SLCO1B1, which encodes the hepatic sinusoidal transporter, OATP1B1. Increased exposure of skeletal muscle to statins increases the risk of mitochondrial dysfunction, calcium signalling disruption, reduced prenylation, atrogin-1 mediated atrophy and pro-apoptotic signalling. Rare variants in several metabolic myopathy genes including CACNA1S, CPT2, LPIN1, PYGM and RYR1 increase myopathy/rhabdomyolysis risk following statin exposure. The immune system is implicated in both conventional statin intolerance/myotoxicity via LILRB5 rs12975366, and a strong association exists between HLA-DRB1*11:01 and anti-HMGCR positive myopathy. Epigenetic factors (miR-499-5p, miR-145) have also been implicated in statin myotoxicity. SRM remains a challenge to the safe and effective use of statins, although consensus strategies to manage SRM have been proposed. Further research is required, including stringent phenotyping of mild SRM through N-of-1 trials coupled to systems pharmacology omics- approaches to identify novel risk factors and provide mechanistic insight.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | statin, pharmacogenomics, muscle toxicity, mitochondria, prenylation, immune system |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Jan 2020 08:55 |
| Last Modified: | 25 Jan 2024 08:21 |
| DOI: | 10.3390/jcm9010022 |
| Open Access URL: | https://doi.org/10.3390/jcm9010022 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3069039 |
Dimensions
Dimensions
